# Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Crohn's Disease

> **NCT07078994** · PHASE2 · RECRUITING · sponsor: **Biocad** · enrollment: 204 (estimated)

## Conditions studied

- Crohn's Disease (CD)

## Interventions

- **BIOLOGICAL:** anti-TL1A monoclonal antibody, low dose
- **BIOLOGICAL:** anti-TL1A monoclonal antibody, medium dose
- **BIOLOGICAL:** anti-TL1A monoclonal antibody, high dose
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07078994
- **Lead sponsor:** Biocad
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-14
- **Primary completion:** 2027-05
- **Final completion:** 2029-01
- **Target enrollment:** 204 (ESTIMATED)
- **Last updated:** 2025-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07078994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07078994, "Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Crohn's Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07078994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*